Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in -Mutant Medullary Thyroid Cancer.

Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported tolerability (PRT). We report the use of a novel, quantifiable PRT metric as a multiplicity-controlled endpoint to support regulatory and clinical decision-making for selpercatinib use. Comparative PRT was assessed in LIBRETTO-531 (NCT04211337), a randomized phase 3 trial of selpercatinib versus vandetanib/cabozantinib (control) in advanced -mutant medullary thyroid cancer (MTC).

Lenvatinib as salvage therapy in advanced and progressive GI-NET.

The efficacy of lenvatinib in treating gastrointestinal neuroendocrine tumors (GI-NETs) has been explored in preclinical studies and early-phase clinical trials, but real-world data remain limited. Data of sixteen patients (median age 65 years; 62.5% female) with advanced and progressive GI-NET who were treated with lenvatinib at the ENETS Center, University Hospital Essen, between July 2019 and February 2024 were analyzed.

Merkel cell carcinoma: long-term outcomes after radiotherapy treatment.

Background: Merkel cell carcinoma (MCC) is a rare, aggressive disease with high relapse and fatality rates. Radiotherapy (RT) is essential for local control, but published data on both initial treatment and relapse management remain limited.

Material And Methods: We retrospectively analyzed 17 patients treated in a single-center with radical and adjuvant RT.

Smoking Adversely Affects Survival of Metastatic Lung Carcinoid Patients: Analysis of a Large International Audit and Prognostic Models for Metastasis-Free Survival and Overall Survival.

Introduction: Among neuroendocrine lung cancers, lung carcinoids (LCs, further divided into typical [TC] and atypical [AC]) are rare, representing only the 2% of all bronchopulmonary malignancies, and lack prognostic classification and stratification.

Methods: We audited 2 international cohorts of patients with a confirmed diagnosis of LC for prognostic analysis. We used data from the Christie Hospital (Manchester, UK, N = 282) and validated our findings using the cohort of Vall d'Hebron Hospital patients (Barcelona, Spain, N = 80).

Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.

As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. Recently published European guidelines on advanced/metastatic TC management include a special focus on biomarker testing. However, to date, there remains a need for comprehensive European guidance for standardized molecular testing strategies in TC that encompass a broad set of targetable or potentially targetable alterations, timing of testing, and patients to be tested.